149 related articles for article (PubMed ID: 34516662)
1. Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
Cho MC; Yoo S; Choo MS; Son H; Jeong H
Prostate; 2021 Dec; 81(16):1278-1286. PubMed ID: 34516662
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
[TBL] [Abstract][Full Text] [Related]
3. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
Schouten MG; van der Leest M; Pokorny M; Hoogenboom M; Barentsz JO; Thompson LC; Fütterer JJ
Eur Urol; 2017 Jun; 71(6):896-903. PubMed ID: 28063613
[TBL] [Abstract][Full Text] [Related]
4. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK
Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
[TBL] [Abstract][Full Text] [Related]
5. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
Caglayan V; Onen E; Avci S; Sambel M; Kilic M; Oner S; Aydos MM; Yıldız HE
Arch Ital Urol Androl; 2019 Jan; 90(4):270-275. PubMed ID: 30655640
[TBL] [Abstract][Full Text] [Related]
7. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
8. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy.
Boesen L; Noergaard N; Chabanova E; Logager V; Balslev I; Mikines K; Thomsen HS
Scand J Urol; 2015 Feb; 49(1):25-34. PubMed ID: 24922550
[TBL] [Abstract][Full Text] [Related]
9. Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy.
Oh JJ; Kwon O; Lee JK; Byun SS; Lee SE; Lee S; Hong SK
Asian J Androl; 2016; 18(6):937-941. PubMed ID: 26470836
[TBL] [Abstract][Full Text] [Related]
10. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
12. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
13. The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy.
Patel N; Cricco-Lizza E; Kasabwala K; Xu C; Robinson BD; Khani F; Wang Y; Margolis D; Hu JC
Eur Urol Oncol; 2018 Sep; 1(4):263-267. PubMed ID: 31100246
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
15. Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?
Abd-Alazeez M; Ahmed HU; Arya M; Allen C; Dikaios N; Freeman A; Emberton M; Kirkham A
Urol Oncol; 2014 Aug; 32(6):741-7. PubMed ID: 24981993
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-lymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2,5-10 ng/ml PSA value.
Ceylan Y; Günlüsoy B; Degirmenci T; Bolat D; Kozacioglu Z; Vardar E; Topçu YK; Polat S
Arch Esp Urol; 2016 Nov; 69(9):627-635. PubMed ID: 27845694
[TBL] [Abstract][Full Text] [Related]
17. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
18. Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models.
Lawrentschuk N; Lockwood G; Davies P; Evans A; Sweet J; Toi A; Fleshner NE
Int Urol Nephrol; 2011 Mar; 43(1):23-30. PubMed ID: 20464485
[TBL] [Abstract][Full Text] [Related]
19. Cancer Location in Upgrading and Detection after Transperineal Template-Guided Mapping Biopsy for Patients in Active Surveillance and Negative Transrectal Ultrasonography-Guided Prostate Biopsy.
Lee CU; Sung SH; Jang CT; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Urol Int; 2019; 103(3):262-269. PubMed ID: 31269509
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.
Schoots IG; Roobol MJ; Nieboer D; Bangma CH; Steyerberg EW; Hunink MG
Eur Urol; 2015 Sep; 68(3):438-50. PubMed ID: 25480312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
